Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LaserSight

This article was originally published in The Gray Sheet

Executive Summary

Refractive laser firm raises $16 mil. via investments of $8 mil. each by Dawson Samberg Capital Management Funds and TLC The Laser Center, Inc. -both consisting of 2 mil. shares of preferred stock at $4 each. The firm received an additional $4.3 mil. on June 5 in connection with the sale of Vision Twenty-One stock received last December in connection with that firm's acquisition of two of LaserSight's health care subsidiaries ("The Gray Sheet" Jan. 5, In Brief). Proceeds will be used for expansion of the firm's international presence and for U.S. marketing activities, as well as debt repayment and repurchase of all Series B preferred stock. LaserSight and TLC are collaborating to develop a mobile excimer laser business...

You may also be interested in...



Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Fledgling Pharma FerGene Makes Quick Debut With Gene Therapy Candidate

FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.

UsernamePublicRestriction

Register

MT010266

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel